Bromide

Bromide

SCHEMBL4772656

Br.O=C(CBr)c1ccncn1

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.55
FAAH O00519 1/20 0.47
CTNNB1 P35222 2/20 0.46
WNT3A P56704 2/20 0.46
GRM4 Q14833 2/20 0.41
TBXA2R P21731 4/20 0.37
GSK3B P49841 5/20 0.36
PTPN1 P18031 3/20 0.36
GSK3A P49840 1/20 0.35
HSP90AA1 P07900 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4190449 0.98 P2RX7 (0.56) P2RX7FAAHCTNNB1WNT3AGRM4
Bromide SCHEMBL28037038 0.81 P2RX7 (0.55) P2RX7FAAHCTNNB1WNT3AGRM4
SCHEMBL882670 0.78 P2RX7 (0.56) P2RX7FAAHCTNNB1WNT3AGRM4
SCHEMBL30481578 0.78 P2RX7 (0.56) P2RX7FAAHCTNNB1WNT3AGRM4
SCHEMBL2293958 0.77 P2RX7 (0.59) P2RX7FAAHCTNNB1WNT3AGRM4
SCHEMBL4363009 0.76 P2RX7 (0.53) P2RX7FAAHCTNNB1WNT3AGRM4
SCHEMBL12208551 0.76 P2RX7 (0.58) P2RX7FAAHCTNNB1WNT3AGRM4
SCHEMBL18906056 0.76 CTNNB1 (0.55) P2RX7FAAHCTNNB1WNT3AGRM4
SCHEMBL5160553 0.76 P2RX7 (0.68) P2RX7FAAHCTNNB1WNT3AGRM4
SCHEMBL11563546 0.76 FAAH (0.64) P2RX7FAAHCTNNB1WNT3AGRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688772-A1 BIARYL DERIVATIVES AND RELATED USES Moma Therapeutics, Inc. (US) 2026-02-11 EP disclosed
US-20260015360-A1 BIARYL DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2026-01-15 US disclosed
WO-2024211834-A1 BIARYL DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. (US) 2024-10-10 WO disclosed
CN-116981667-A Heterocyclic inhibitors of EGFR and/or HER2 for cancer treatment 蝎子疗法股份有限公司 2023-10-31 CN disclosed
EP-1660475-B1 PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PFIZER ITALIA SRL (IT) 2008-05-28 EP disclosed
US-7279575-B2 Pyrimidylpyrrole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2007-10-09 US disclosed
EP-1660475-A1 PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2006-05-31 EP disclosed
US-20050043323-A1 Pyrimidylpyrrole derivatives active as kinase inhibitors PHARMACIA ITALIA S.P.A. (IT) 2005-02-24 US disclosed
WO-2005014572-A1 PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015360-A1 BIARYL DERIVATIVES AND RELATED USES POLB, POLA1, POLN P2RX7 2849/4885FAAH 2403/4885CTNNB1 460/4885
US-20050043323-A1 Pyrimidylpyrrole derivatives active as kinase inhibitors TYMP, DTYMK, DCK P2RX7 1341/4885FAAH 4807/4885CTNNB1 2865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.